{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:56:44Z","timestamp":1770987404732,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:00:00Z","timestamp":1585353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:00:00Z","timestamp":1585353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00432-020-03198-7","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T11:02:37Z","timestamp":1585393357000},"page":"1575-1582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review"],"prefix":"10.1007","volume":"146","author":[{"given":"Juan","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,28]]},"reference":[{"key":"3198_CR1","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park JH, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu JR, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38","journal-title":"Sci Transl Med"},{"key":"3198_CR2","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:3321\u20133330","journal-title":"Blood"},{"key":"3198_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN (2018) Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 15:31\u201346","journal-title":"Nat Rev Clin Oncol"},{"key":"3198_CR4","doi-asserted-by":"publisher","first-page":"e82742","DOI":"10.1371\/journal.pone.0082742","volume":"8","author":"LE Budde","year":"2013","unstructured":"Budde LE, Berger C, Lin Y, Wang JJ, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW (2013) Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS ONE 8:e82742","journal-title":"PLoS ONE"},{"key":"3198_CR5","doi-asserted-by":"crossref","unstructured":"Du J, Zhang Y (2019) Sequential anti-CD19, anti-CD22, and anti-CD20 autologous chimeric antigen receptor T cell (CAR-T) therapies treating a child with relapsed refractory Burkitt lymphoma. In: 34th Annual meeting and pre-conference programs of the society for immunotherapy of cancer. J Immunother Cancer 7:S1","DOI":"10.1007\/s00432-020-03198-7"},{"key":"3198_CR6","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT (2017) Cytokine release syndromeafter chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 45:e124\u2013e131","journal-title":"Crit Care Med"},{"issue":"1","key":"3198_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24(1):20\u201328","journal-title":"Nat Med"},{"key":"3198_CR8","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi L, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, Turtle CJ (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127:2406\u20132410","journal-title":"Blood"},{"key":"3198_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","volume":"30","author":"S Gill","year":"2016","unstructured":"Gill S, Maus MV, Porter DL (2016) Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev 30:157\u2013167","journal-title":"Blood Rev"},{"key":"3198_CR10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121:1165\u20131174","journal-title":"Blood"},{"key":"3198_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","volume":"27","author":"LA Johnson","year":"2017","unstructured":"Johnson LA, June CH (2017) Driving gene-engineered T cell immunotherapy of cancer. Cell Res 27:38\u201358","journal-title":"Cell Res"},{"key":"3198_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3324\/haematol.2014.121434","volume":"100","author":"A Jourdain","year":"2015","unstructured":"Jourdain A, Auperin A, Minard-Colin V, Aladjidi N, Zsiros J, Coze C (2015) Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \u201clymphomes malins B\u201d protocols. A soci\u00e9t\u00e9 fran\u00e7aise des cancers de l\u2019enfant study. Haematologica 100:810\u2013817","journal-title":"Haematologica"},{"key":"3198_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/0167-5699(94)90273-9","volume":"15","author":"JH Kehrl","year":"1994","unstructured":"Kehrl JH, Riva A, Wilson GL, Thevenin C (1994) Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 15:432\u2013436","journal-title":"Immunol Today"},{"key":"3198_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195","journal-title":"Blood"},{"issue":"2","key":"3198_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, Wu T, Chen D, Chang AH, Gao Z, Song Y, Zhao Y, Tong C (2020) Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J 10(2):15","journal-title":"Blood Cancer J"},{"key":"3198_CR16","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","volume":"33","author":"V Minard-Colin","year":"2015","unstructured":"Minard-Colin V, Brugieres L, Reiter A, Cairo MS, Gross TG, Woessmann W (2015) Non-hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol 33:2963\u20132974","journal-title":"J Clin Oncol"},{"key":"3198_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ (2018) Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. Nat Rev Clin Oncol 15:47\u201362","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3198_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR-T cells. Nat Med 24(6):739\u2013748","journal-title":"Nat Med"},{"key":"3198_CR19","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","volume":"33","author":"J Pan","year":"2019","unstructured":"Pan J, Niu Q, Deng BP et al (2019) CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 33:2854\u20132866","journal-title":"Leukemia"},{"key":"3198_CR20","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1200\/JCO.2016.34.15_suppl.7003","volume":"34","author":"JH Park","year":"2016","unstructured":"Park JH, Riviere I, Wang X, Purdon T, Sadelain M, Brentjens RJ (2016) Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. J Clin Oncol 34:7003","journal-title":"J Clin Oncol"},{"issue":"5","key":"3198_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Brigitte S, Currran KJ (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459","journal-title":"N Engl J Med"},{"key":"3198_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","volume":"67","author":"CA Ramos","year":"2016","unstructured":"Ramos CA, Heslop HE, Brenner MK (2016) CAR-T cell therapy for lymphoma. Ann Rev Med 67:165\u2013183","journal-title":"Ann Rev Med"},{"key":"3198_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","volume":"58","author":"S Raponi","year":"2011","unstructured":"Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, Perbellini O, Pizzolo G, Foa R, Guarini A (2011) Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 58:1098\u20131107","journal-title":"Leuk Lymphoma"},{"key":"3198_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1479-5876-11-150","volume":"11","author":"JL Reagan","year":"2013","unstructured":"Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ (2013) Cellular immunotherapy for refractory hematological malignancies. J Transl Med 11:150","journal-title":"J Transl Med"},{"key":"3198_CR25","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE (2018) Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 24:1499\u20131503","journal-title":"Nat Med"},{"issue":"1","key":"3198_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","volume":"5","author":"D Schneider","year":"2017","unstructured":"Schneider D, Xiong Y, Wu D, Nolle V, Haso W (2017) A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer 5(1):42","journal-title":"J Immunother Cancer"},{"key":"3198_CR27","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282\u20131295","journal-title":"Cancer Discov"},{"key":"3198_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR (2015) Engineering CAR-T cells: design concepts. Trends Immunol 36:494\u2013502","journal-title":"Trends Immunol"},{"key":"3198_CR29","unstructured":"US Department of Health and Human Services (2010) Common terminology criteria for adverse events. V4.03: 14 June 2010"},{"key":"3198_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","volume":"343","author":"XJ Xu","year":"2014","unstructured":"Xu XJ, Tang YM (2014) Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 343:172\u2013178","journal-title":"Cancer Lett"}],"updated-by":[{"DOI":"10.1007\/s00432-020-03269-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000}}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03198-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-020-03198-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03198-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:16:26Z","timestamp":1616890586000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-020-03198-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,28]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["3198"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03198-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00432-020-03269-9","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,28]]},"assertion":[{"value":"31 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original article published, the first author\ufffd\ufffd\ufffds affiliation is incorrect.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient\u2019s guardian for the analysis of the samples and the tissues. Consent for publication was obtained from the patient\u2019s guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}